Company intelligence / Profile preview

Wuxi Zhikang Hongyi Biological Technology

Ownership: Private
Development stage: Commercial

Overview

Wuxi Zhikang Hongyi Biological Technology is a biopharmaceutical company focused on the discovery, development, clinical trials, and commercialization of innovative drugs targeting major diseases such as cancer and chronic kidney disease. The company has multiple programs in late-stage clinical development including small molecules and biologics across oncology and nephrology indications. Its lead asset is in Phase 3 for proteinuria; other assets are in various stages up to Phase 2 for solid tumors.

Therapeutic areas: OncologyNephrology
Modalities: Small moleculeMonoclonal antibodyAntibody-drug conjugateBispecific monoclonal antibody
Industry: Biotech

Drug pipeline

2 assets

WBP3425

Unknown

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Wuxi Zhikang Hongyi Biological Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wuxi Zhikang Hongyi Biological Technology.

Explore the full profile